ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001.

Introduction: Analgesics are among the most widely used drugs worldwide. The French Addictovigilance Network (FAN) established the antalgiques stupéfiants et ordonnances sécurisées (ASOS [narcotic analgesics and secure prescriptions]) survey in order to assess the dissemination of tamper-resistant prescription forms for narcotic analgesic within the medical community, as well as the nature and evolution of the prescriptions. After outlining the missions of the FAN, this article will describe the population treated with narcotic analgesics in France, their therapeutic indications and how the data have evolved since 2007.

Emerging Detection of Hexahydrocannabinol in Driver Saliva: Preliminary Data.

Introduction: Hexahydrocannabinol or HHC has recently appeared on the Internet and in cannabidiol (CBD) stores in various forms. Although the abuse and dependence potential of HHC consumption has not yet been established, HHC has been reported by consumers to have effects similar to delta-9-tetrahydrocannabinol (THC) and has been classified as narcotics in France since June 12, 2023.

Methods: We conducted a retrospective study of all cases of oral fluid samples collected from drivers by traffic police officers and sent to our laboratory to confirm the presence of illicit substances between June 12, 2023 and December 31, 2023.

From regional signal to alert in addictovigilance.

France has several monitoring systems that form the foundation of its health safety surveillance. This system is designed for the early detection of signals and their swift into an action system that enables timely, appropriate, and effective interventions to protect public health. These signals are considered alerts when sufficiently validated after an initial risk assessment and if they represent a potential threat to public health, necessitating an appropriate response.

EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner.

Poly ADP-ribose polymerase inhibitors (PARPi) are first-line maintenance therapy for ovarian cancer and an alternative therapy for several other cancer types. However, PARPi-resistance is rising, and there is currently an unmet need to combat PARPi-resistant tumors. Here, we created an immunocompetent, PARPi-resistant mouse model to test the efficacy of combinatory PARPi and euchromatic histone methyltransferase 1/2 inhibitor (EHMTi) in the treatment of PARPi-resistant ovarian cancer.